Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study

Joo, Sung Woo; Shon, Seung‐Hyun; Choi, GumJee; Koh, MinJung; Cho, Seung Woo; Lee, Jung Sun

doi:10.1016/j.euroneuro.2019.07.138

Cited by 13 publications

(16 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Results from our study are in line with previous publications that patients on paliperidone palmitate have a higher treatment continuation than patients on risperidone microspheres [ 19 , 20 , 24 ]. We also found that PP3M patients have a significantly lower treatment discontinuation than PP1M patients (19.2% vs 37.1%, p < 0.001) in the one-year follow up.…”

Section: Discussionsupporting

confidence: 92%

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Cai¹,

Decuypere²,

Chevalier³

et al. 2022

BMC Psychiatry

View full text Add to dashboard Cite

Background Long-acting antipsychotics (e.g. 1-monthly (PP1M) / 3-monthly (PP3M) injection forms of paliperidone palmitate) have been developed to improve treatment continuation in schizophrenia patients. We aim to assess risk factors of treatment discontinuation of patients on paliperidone palmitate and risperidone microsphere. Additionally, treatment discontinuation between patients with PP1M and PP3M was compared. Methods The IQVIA Longitudinal Prescription databases were used. Risk factors of treatment discontinuation were identified by a multilevel survival regression using Cox proportional hazards model. Kaplan Meier analyses were performed by identified significant risk factors. Results Twenty-five thousand three hundred sixty-one patients (France: 9,720; Germany: 14,461; Belgium: 1,180) were included. Over a one-year follow-up period, a significant lower treatment discontinuation was observed for patients newly initiated on paliperidone palmitate (53.8%) than those on risperidone microspheres (85.4%). Additionally, a significantly lower treatment discontinuation was found for ‘stable’ PP3M patients (19.2%) than ‘stable’ PP1M patients (37.1%). Patients were more likely to discontinue when drugs were prescribed by GP only (HR = 1.68, p < 0.001 vs. psychiatrist only) or if they were female (HR = 1.07, p < 0.001), whereas discontinuation decreased with age (31–50 years: HR = 0.95, p = 0.006 and > 50 years: HR = 0.91, p < 0.001 vs. 18–30 years). Conclusions This study demonstrates that patients stay significantly longer on treatment when initiated on paliperidone palmitate as compared to risperidone microspheres. It also indicated a higher treatment continuation of PP3M over PP1M. Treatment continuation is likely to be improved by empowering GPs with mental health knowledge and managing patients by a collaborative primary care-mental health model. Further research is needed to understand why females and younger patients have more treatment discontinuation.

show abstract

Section: Discussionsupporting

confidence: 92%

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Cai¹,

Decuypere²,

Chevalier³

et al. 2022

BMC Psychiatry

View full text Add to dashboard Cite

show abstract

“…Similar high prescription rates have been reported in clinical practice globally, including several studies from the United States of America, 23 , 28 , 29 , 30 , 54 Nigeria, 31 SA 26 and Korea. 55 The authors explain that some of the patients in these studies had recently been discharged from psychiatric institutions and that either the oral antipsychotic supplementation was used to augment the LAI – AP during the period of stabilisation or that they were being ‘weaned off’ oral antipsychotics that had been initiated during hospitalisation. 23 , 30 , 54 However, our finding is significant because ours was a community clinic-based sample of patients, many of whom had been prescribed this combination for prolonged periods.…”

Section: Discussionmentioning

confidence: 99%

Prescribing patterns of long-acting injectable antipsychotics in a community setting in South Africa

Veyej

Moosa

2022

South African Journal of Psychiatry

View full text Add to dashboard Cite

Background: Long-acting injectable antipsychotics (LAI – APs) improve adherence to antipsychotics and decrease functional decline in schizophrenia. Yet they are prescribed late, in patients with established functional decline. Although LAI – APs are widely prescribed in South Africa, there is a paucity of research regarding the prescription profile for LAI – APs.Aim: This study aimed to describe prescribing practices for LAI – APs at psychiatric clinics.Setting: Community psychiatric clinics in South Africa.Methods: A retrospective review of the psychiatric files of all patients on LAI – APs attending the clinics over the study period was conducted. Sociodemographic, clinical and pharmacological information regarding the LAI – AP prescribed was extracted from the files.Results: A total of 206 charts were examined. The mean age of the study population was 46 (SD ± 12) years. Significantly more patients were male (n = 154; 74.8%), single (n = 184, 89.3%) and unemployed (n = 115; 55.8%) (p 0.001). Approximately half had a comorbid substance use disorder (47.6%). The most common indication for the prescription of a LAI – AP was non-adherence (66%). Only 9.7% of the patients were prescribed a LAI – AP alone. No significant socio-demographic or clinical characteristic was associated with this prescribing habit. A LAI – AP was prescribed in combination with an oral antipsychotic, mood stabiliser or antidepressant in 53.9%, 44.7% and 7.8% of patients, respectively.Conclusion: Long-acting injectable antipsychotics were prescribed mainly following noncompliance with oral antipsychotics and may represent a missed opportunity to prevent functional decline. The high prevalence of LAI – AP polypharmacy has been highlighted.

show abstract

“…Joo et al 28 calculated the proportion of continuous use of LAI antipsychotics at 6 months after initiation using the Health Insurance Review Agency (HIRA) database in South Korea. LAI paliperidone had a significantly higher continuation rate (57.5%) than LAI haloperidol (36.8%) and LAI risperidone (34.5%).…”

Section: Discussionmentioning

confidence: 99%

Persistence With and Adherence to Paliperidone Palmitate Once-Monthly Injection for Schizophrenia Treatment in China and Japan

Wang¹,

Zhang²,

Liu³

et al. 2021

J. Clin. Psychiatry

View full text Add to dashboard Cite

show abstract

Continuation of schizophrenia treatment with three long-acting injectable antipsychotics in South Korea: A nationwide population-based study

Cited by 13 publications

References 23 publications

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Assessment of risk factors of treatment discontinuation among patients on paliperidone palmitate and risperidone microspheres in France, Germany and Belgium

Prescribing patterns of long-acting injectable antipsychotics in a community setting in South Africa

Persistence With and Adherence to Paliperidone Palmitate Once-Monthly Injection for Schizophrenia Treatment in China and Japan

Contact Info

Product

Resources

About